CELLULAR THERAPY OF CANCER WITH TUMOR PRIMED ANTI CD3 ACTIVATED LYMPHOCYTES

这是一项评估免疫T细胞的有效性的研究，在实验室中生长和激活，用于治疗转移性肾细胞癌患者。在动物实验中，免疫T细胞在荷瘤动物体内的转移对晚期肿瘤的消退是非常有效的。在这项研究中，研究人员将通过将患者自身的肿瘤细胞与细菌免疫刺激剂卡介苗混合接种，来评估产生免疫T细胞的能力。这导致疫苗部位的炎症反应活跃，以及邻近疫苗部位的引流淋巴结扩大。淋巴结将在接种疫苗后7 -10天手术切除。这些淋巴结随后将在实验室中利用一种被称为抗cd3的单克隆抗体被激活。这将导致淋巴结细胞被激活，并允许一种名为IL-2的免疫激素扩张。一旦这些细胞大量生长，它们将被输注到患者体内，同时给予IL-2治疗残留的转移性疾病。这是一项II期试验，将有助于确定这种疗法在IV期肾细胞癌患者中的反应率。在实验室中测量的细胞的免疫反应性将与患者观察到的肿瘤反应相关联。

This is a study to evaluate the effectiveness of immune T cells, grown and activated in the laboratory, to be utilized in the treatment of patients with metastatic renal cell cancer. In animal studies, the transfer of immune T cells in tumor bearing animals are highly effective in causing the regression of advanced tumors. In this study, the investigators will evaluate the ability to generate immune T cells by vaccinating patients with their own tumor cells mixed with a bacterial immune stimulating agent, BCG. This results in a brisk inflammatory response at the vaccine site as well as enlargement of draining lymph nodes adjacent to the vaccine site. The lymph nodes will be surgically removed after a 7 -10 day period from the time of the vaccine. These lymph nodes will then be activated in the laboratory utilizing a monoclonal antibody known as anti-CD3. This will cause the lymph node cells to become activated and allow expansion in an immune hormone called IL-2. Once these cells have grown in much larger numbers, they will be used for infusion into the patients along with the administration of IL-2 for the treatment of residual metastatic disease. This represents a phase II trial which will help determine what the response rate of this therapy will be in patients with stage IV renal cell carcinoma. The immunological reactivity of the cells as measured in the laboratory will be correlated with tumor responses observed in patients.